Analysts expect revenue increase UCB

Tomorrow the Belgian company UCB will publish its past quarter's results. For this year UCB 's revenue will be around 4,56 billion euros. This is according to the average of the analysts' estimates. This is slightly more than 2017's revenue of 4,53 billion euros.

Historical revenues and results UCB plus estimates 2018

The analysts expect for 2018 a net profit of 865 million euros. For this year most of the analysts expect a profit per share of 4,58 euros. So the price/earnings-ratio equals 15,57.

Analysts expect a dividend of 1,19 euros per share. The dividend yield is then 1,67 percent. The average dividend yield of the pharmaceutical companies equals a poor 0,5 percent.

Recent target prices around 70 euros

The most recent recommendations for the pharmaceutical company are from Deutsche Bank, Barclays and Jefferies & Co..

UCB 's market capitalization is based on the number of outstanding shares around 13,45 billion euros. The UCB stock was the past 12 months quite unstable. Since last October the stock is 17 percent higher. This year the stock price moved between 60 and 81 euro. Since 2008 the stock price is almost 247 percent higher.

On Friday the stock closed at 71,3 euros.

Historical stock prices UCB

ValueSpectrum.com News Wire & Equity Research: +31 084-0032-842
news@valuespectrum.com

Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.